US · MESO · BIOTECHNOLOGY
Mesoblast Limited (MESO) intrinsic value and stock valuation
$10.89as of 2026-11-21 · Mkt cap 1.94B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Mesoblast Limited DCF and intrinsic value
InvestorsCraft values MESO with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from MESO’s statements →
Mesoblast Limited Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $17.2M | $5.9M | $7.5M | $10.2M | $7.46M |
| Operating income | -$-62.44M | -$-84.15M | -$-69.29M | -$-80.57M | -$-109.1M |
| Net income | -$-102.14M | -$-87.96M | -$-81.89M | -$-91.35M | -$-98.81M |
| EPSd | -$-845.67K | -$-891.46K | -$-975.69K | -$-1.34M | -$-1.63M |
| Operating cash flow | -$-49.95M | -$-48.46M | -$-63.27M | -$-65.78M | -$-106.68M |
| Capital expenditure | -$-730K | -$-330K | -$-310K | -$-230K | -$-1.65M |
| Free cash flow | -$-50.68M | -$-48.79M | -$-63.58M | -$-66.01M | -$-108.33M |
| Total assets | $784.7M | $669.2M | $669.4M | $662.1M | $744.7M |
| Total debt | $128.2M | $118.9M | $116.5M | $106.9M | $105.5M |
| Net debt | -$-33M | $56.4M | $45.6M | $46.9M | -$-31.39M |
| Total equity | $597.4M | $480.4M | $501.8M | $497M | $581.4M |
| Cash and short-term investments | $161.2M | $62.6M | $70.9M | $60M | $136.9M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $17.2M | $5.9M | $7.5M | $10.2M | $7.46M |
| Cost of revenue | $5.13M | $41.1M | $54.9M | $63.6M | $85.7M |
| Gross profit | $12.1M | -$-35.17M | -$-47.42M | -$-53.36M | -$-78.28M |
| Research and development expenses | $34.8M | $25.4M | $27.2M | $32.8M | $53M |
| Selling, general and administrative expenses | $39.3M | $23.6M | $53.1M | $58M | $63.6M |
| Other expenses | $400K | $0.00 | $0.00 | $30.8M | $32.7M |
| Operating expenses | $74.5M | $49M | $76.8M | $90.8M | $115.1M |
| Cost and expenses | $79.6M | $90.1M | $76.8M | $90.8M | $115.1M |
| Interest income | $3.55M | $1.82M | $830K | $0.00 | $0.00 |
| Interest expense | $22.9M | $20.7M | $19.4M | $17.3M | $10.7M |
| Depreciation and amortization | $6.4M | $1.9M | $4.11M | $4.38M | $4.26M |
| Ebitda | -$-73.66M | -$-56.08M | -$-58.55M | -$-76.57M | -$-84.65M |
| Operating income | -$-62.44M | -$-84.15M | -$-69.29M | -$-80.57M | -$-109.1M |
| Total other income/expenses, net | -$-39.37M | -$-4M | -$-12.81M | -$-10.48M | $9.47M |
| Income before tax | -$-101.81M | -$-88.15M | -$-82.1M | -$-91.59M | -$-99.63M |
| Income tax expense | $330K | -$-190K | -$-210K | -$-240K | -$-820K |
| Net income | -$-102.14M | -$-87.96M | -$-81.89M | -$-91.35M | -$-98.81M |
| Weighted average shares outstanding | $120.8M | $98.7M | $83.8M | $68.3M | $60.5M |
| Weighted average diluted shares outstanding | $120.8M | $98.7M | $83.9M | $68.3M | $60.5M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $161.2M | $62.6M | $70.9M | $60M | $136.9M |
| Net receivables | $14.9M | $21M | $7M | $4.4M | $4.59M |
| Inventory | $22.3M | $0.00 | $0.00 | $0.00 | -$-250K |
| Total current assets | $204.4M | $86.5M | $81.7M | $69.8M | $148.2M |
| Property, plant and equipment, net | $5.82M | $3.84M | $6.49M | $9.96M | $12.1M |
| Goodwill and intangible assets | $571.8M | $575.7M | $577.2M | $578.7M | $580.6M |
| Long-term investments | $1.39M | $1.01M | $1.76M | $1.76M | $2.08M |
| Total non-current assets | $580.3M | $582.7M | $587.8M | $592.3M | $596.5M |
| Total assets | $784.7M | $669.2M | $669.4M | $662.1M | $744.7M |
| Accounts payable | $19.1M | $7.07M | $20.1M | $23.1M | $19.6M |
| Short-term debt | $56.8M | $16.5M | $10M | $8.2M | $56M |
| Deferred revenue | $0.00 | $0.00 | $6.4M | $17.9M | -$-55.97M |
| Total current liabilities | $102.6M | $73.2M | $42M | $51.4M | $94.3M |
| Long-term debt | $71.3M | $102.4M | $106.5M | $98.7M | $49.5M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $84.6M | $115.6M | $125.6M | $113.7M | $69.1M |
| Capital lease obligations | $6.26M | $4.58M | $7.73M | $10.3M | $11.3M |
| Total liabilities | $187.2M | $188.8M | $167.6M | $165.1M | $163.3M |
| Common stock | $1.51B | $1.31B | $1.25B | $1.17B | $1.16B |
| Retained earnings | -$-1.01B | -$-908.76M | -$-820.8M | -$-738.92M | -$-647.57M |
| Accumulated other comprehensive income (loss) | $99.5M | $78.3M | $73.5M | $70.7M | $65.8M |
| Total equity | $597.4M | $480.4M | $501.8M | $497M | $581.4M |
| Total investments | $1.39M | $1.01M | $1.76M | $1.76M | $2.08M |
| Total debt | $128.2M | $118.9M | $116.5M | $106.9M | $105.5M |
| Net debt | -$-33M | $56.4M | $45.6M | $46.9M | -$-31.39M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-102.14M | -$-87.96M | -$-81.89M | -$-91.35M | -$-98.81M |
| Depreciation and amortization | $6.4M | $4.67M | $4.11M | $4.38M | $4.26M |
| Stock-based compensation | $22.1M | $5.87M | $3.65M | $5.54M | $12.5M |
| Change in working capital | -$-3.04M | -$-2.63M | -$-2.47M | $4.87M | -$-8.42M |
| Accounts receivable | $6.29M | -$-15.47M | -$-120K | $140K | -$-1.74M |
| Inventory | $830K | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash provided by operating activities | -$-49.95M | -$-48.46M | -$-63.27M | -$-65.78M | -$-106.68M |
| Investments in property, plant and equipment | -$-680K | -$-270K | -$-310K | -$-230K | -$-1.65M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | $120K | -$-100K | -$-190K | -$-230K | -$-1.65M |
| Common stock issued | $161.2M | $65.4M | $88.6M | $210K | $106.3M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $147.3M | $40.3M | $74.5M | -$-9.87M | $114.5M |
| Net change in cash | $98.6M | -$-8.36M | $10.9M | -$-76.43M | $7.55M |
| Cash at end of period | $161.6M | $63M | $71.3M | $60.5M | $136.9M |
| Operating cash flow | -$-49.95M | -$-48.46M | -$-63.27M | -$-65.78M | -$-106.68M |
| Capital expenditure | -$-730K | -$-330K | -$-310K | -$-230K | -$-1.65M |
| Free cash flow | -$-50.68M | -$-48.79M | -$-63.58M | -$-66.01M | -$-108.33M |
Line items
Line items
Line items
About Mesoblast Limited
Mesoblast Limited is a biopharmaceutical firm dedicated to the development and commercialization of allogeneic cell-based therapies. Its global presence extends across the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company addresses a broad spectrum of medical conditions, including cardiovascular, spinal orthopedic disorders, oncology, hematology, and immune-mediated and inflammatory diseases. At the core of its innovation is a proprietary regenerative medicine platform utilizing specialized mesenchymal lineage cells. Currently, several of Mesoblast's leading product candidates are undergoing Phase III clinical trials: remestemcel-L, designed for severe, steroid-refractory acute graft versus host disease and acute respiratory distress syndrome associated with COVID-19; Rexlemestrocel-L, aimed at advanced chronic heart failure; and MPC-06-ID, intended for chronic low back pain stemming from degenerative disc disease. Additionally, MPC-300-IV is being developed for biologic-refractory rheumatoid arthritis and diabetic nephropathy. The company has cultivated strategic partnerships to advance its pipeline and market reach. These collaborations include Tasly Pharmaceutical Group for the distribution of MPC-150-IM (heart failure) and MPC-25-IC (heart attacks) in China; JCR Pharmaceuticals Co. Ltd. for therapies addressing wound healing in patients with epidermolysis bullosa; and Grünenthal for the development and commercialization of cell therapy solutions for chronic low back pain. Mesoblast Limited was established in 2004 and maintains its headquarters in Melbourne, Australia.
- CEO
- Silviu Itescu
- Employees
- 81
- Beta
- 0.81
Explore
Frequently asked questions
What is the intrinsic value of Mesoblast Limited (MESO)?
Mesoblast Limited (MESO) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is MESO undervalued?
MESO trades at a price of $10.89 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.